Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials